TABLE 3 .
Nintedanib potently inhibits the proliferation of cell lines carrying alterations in PDGFRA or FGFR2
Data were determined using an alamarBlue Cell Viability Assay Protocol from the Cell Proliferation Assay Protocols section of Life Technologies, drug exposure for 72 hours.
| EC50 (nmol/l) | NCI-1703 PDGFRA ampl | KatoIII FGFR2 ampl. | AN3CA FGFR2 mut. | MFM-223 FGFR2 ampl. |
|---|---|---|---|---|
| Nintedanib | 10 ± 3 | 176 ± 40 | 152 ± 22 | 108 |
| PD173074 | n.a. | 30 ± 5 | n.a. | n.a. |
| Imatinib | 109 ± 65 | n.a. | n.a. | n.a. |
| Sunitinib | 39 ± 10 | 624 ± 85 | n.a. | n.a. |
| Sorafenib | 258 ± 25 | 383 ± 24 | n.a. | n.a. |
n.a., not applicable.